Crinetics Pharmaceuticals, Inc. 4

Vivaldi Coelho Rogerio had 19,225 Crinetics common shares and 93,830 in‑the‑money stock options canceled and cashed out at the $85.00 per‑share merger price (or its spread) upon Crinetics’ acquisition by Vertex Pharmaceuticals.

On September 1, 2026, in connection with the closing of Vertex Pharmaceuticals’ acquisition of Crinetics Pharmaceuticals at $85.00 per share in cash, all of Vivaldi Coelho Rogerio’s equity in Crinetics was canceled and cashed out. A total of 19,225 shares of common stock (13,300 and 5,925 share blocks) were converted into cash at $85.00 per share, and multiple tranches of vested stock options with exercise prices below $85.00 were canceled in exchange for cash equal to the spread between the $85.00 merger price and each option’s exercise price. Specifically, cash‑settled options included: 35,000 options at a $28.31 strike (spread $56.69), 8,750 options at $18.29 (spread $66.71), 17,500 options at $20.32 (spread $64.68), 12,500 options at $44.71 (spread $40.29), 10,350 options at $32.33 (spread $52.67), and 9,730 options at $35.87 (spread $49.13). Following these merger-related cancellations and cash payments, the reporting person held no remaining Crinetics common stock or stock options, as Crinetics became a wholly owned subsidiary of Vertex and its public equity was eliminated.

Filing Facts

CIK

1658247

Ticker

CRNX

Form

4

Source Type

fda

Accession

0001628280-26-059907

Alert Tier

6